ME00935B - Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću - Google Patents

Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću

Info

Publication number
ME00935B
ME00935B MEP-2009-299A MEP29909A ME00935B ME 00935 B ME00935 B ME 00935B ME P29909 A MEP29909 A ME P29909A ME 00935 B ME00935 B ME 00935B
Authority
ME
Montenegro
Prior art keywords
cyclopropylmethoxy
carboxamide
dichloro
methoxy
parkinson
Prior art date
Application number
MEP-2009-299A
Other languages
English (en)
French (fr)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ME00935B publication Critical patent/ME00935B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pronalazak se odnosi na upotrebu 4-ciklopropilmetoksi- N -(3,5-dihloro-1-oksidpiridin- 4-il)-5-(metoksi)piridin-karboksamida za dobijanje leka za lečenje motoričkih  5 poremećaja povezanih sa Parkinsonovom bolešću .

Claims (2)

1.Upotreba 4-ciklopropilmetoksi-N-(3,5-dih loro-1-oksido-piridin-4-il)-5- (metoksi)piridin-2- karboksamida, u obliku hidrata, solvata, baze ili adicione soli sa kiselinom, za dobijanje leka za lečenje motoričkih poremećaja povezanih sa Parkinsonovom bolešću .
2. Upotreba prema za htevu l , naznačena time, što je 4-ciklopropilmetoksi-N-(3,5- dihloro-1-oksido-piridin-4-il)-5-(metoksi)piridin-2- karboksamid u obliku baze.
MEP-2009-299A 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću ME00935B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
ME00935B true ME00935B (me) 2012-06-20

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-299A ME00935B (me) 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću

Country Status (33)

Country Link
US (1) US20100130554A1 (me)
EP (1) EP2146714B1 (me)
JP (1) JP5386478B2 (me)
KR (2) KR20150004885A (me)
CN (1) CN101663035B (me)
AR (1) AR066108A1 (me)
AT (1) ATE513548T1 (me)
AU (1) AU2008257322B2 (me)
BR (1) BRPI0810444A2 (me)
CA (1) CA2684174C (me)
CL (1) CL2008001136A1 (me)
CY (1) CY1111840T1 (me)
DK (1) DK2146714T3 (me)
EA (1) EA019194B1 (me)
ES (1) ES2367408T3 (me)
FR (1) FR2915100B1 (me)
HR (1) HRP20110666T1 (me)
IL (1) IL201448A (me)
JO (1) JO2678B1 (me)
MA (1) MA31367B1 (me)
ME (1) ME00935B (me)
MX (1) MX2009011284A (me)
MY (1) MY148092A (me)
NZ (1) NZ580482A (me)
PA (1) PA8776801A1 (me)
PL (1) PL2146714T3 (me)
PT (1) PT2146714E (me)
RS (1) RS51869B (me)
SI (1) SI2146714T1 (me)
TW (1) TWI439269B (me)
UY (1) UY31035A1 (me)
WO (1) WO2008145841A1 (me)
ZA (1) ZA200907251B (me)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533953B2 (en) * 2012-11-28 2017-01-03 Sanofi Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ES2176251T3 (es) * 1993-07-28 2002-12-01 Aventis Pharma Ltd Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
CA2518513C (en) * 2003-03-12 2014-05-20 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
KR20090130059A (ko) 2009-12-17
NZ580482A (en) 2011-10-28
KR101503942B1 (ko) 2015-03-18
AU2008257322B2 (en) 2013-06-13
JP2010524906A (ja) 2010-07-22
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
MY148092A (en) 2013-02-28
CN101663035A (zh) 2010-03-03
EP2146714B1 (fr) 2011-06-22
AR066108A1 (es) 2009-07-22
FR2915100B1 (fr) 2009-06-05
EP2146714A1 (fr) 2010-01-27
SI2146714T1 (sl) 2011-10-28
PL2146714T3 (pl) 2011-10-31
TWI439269B (zh) 2014-06-01
JP5386478B2 (ja) 2014-01-15
IL201448A0 (en) 2010-05-31
WO2008145841A1 (fr) 2008-12-04
FR2915100A1 (fr) 2008-10-24
US20100130554A1 (en) 2010-05-27
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
UY31035A1 (es) 2008-11-28
HRP20110666T1 (hr) 2011-10-31
PA8776801A1 (es) 2008-11-19
AU2008257322A1 (en) 2008-12-04
ES2367408T3 (es) 2011-11-03
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CN101663035B (zh) 2012-06-20
CA2684174A1 (fr) 2008-12-04
CY1111840T1 (el) 2015-10-07
MX2009011284A (es) 2009-11-02
CA2684174C (fr) 2014-02-25
ZA200907251B (en) 2011-04-28
TW200911247A (en) 2009-03-16
HK1141725A1 (en) 2010-11-19
CL2008001136A1 (es) 2009-01-16
MA31367B1 (fr) 2010-05-03
KR20150004885A (ko) 2015-01-13
EA200970970A1 (ru) 2010-02-26
ATE513548T1 (de) 2011-07-15
IL201448A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
HRP20050710A2 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
TN2015000356A1 (en) Bicyclic compounds
ME00935B (me) Upotreba 4-ciklopropilmetoksi-&lt;i&gt;n&lt;/i&gt;-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
HRP20110459T1 (hr) Upotreba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju ozljeda kralježnične moždine
WO2007012479A3 (en) Benzylpiperazine derivates and their medical use
ME01273B (me) Upotreba 4-ciklopropilmetoksi-n-(3,5-dihloro-1- oksidopiridin-4- il)-5-(metoksi)piridin-2-karboksamida za liječenje povreda lobanje
WO2015036898A3 (en) Novel salts of crizotinib and their preparation
TH98781B (th) สารเตรียมแบบผสมที่ประกอบด้วย ไบฟีพรูนอกซ์ และ ตัวทำการโดปามีน